Results 31 to 40 of about 14,797,528 (308)
Frontiers in Pharmacology, 2021 Background: Identifying patients with de novo acute myeloid leukemia (AML) who will probably respond to the “7 + 3” induction regimen remains an unsolved clinical challenge.
Tzu-Hung Hsiao +15 more
doaj +1 more source
c-Myc and Cancer Metabolism [PDF]
Clinical Cancer Research, 2012 Abstract The processes of cellular growth regulation and cellular metabolism are closely interrelated. The c-Myc oncogene is a “master regulator” which controls many aspects of both of these processes. The metabolic changes which occur in transformed cells, many of which are driven by c-Myc overexpression, are necessary to support the ...
Donald M, Miller +4 more
openaire +2 more sources
Stem Cell Research & Therapy, 2019 Background Mesenchymal stromal cells isolated from bone marrow (MSC) represent an attractive source of adult stem cells for regenerative medicine. However, thorough research is required into their clinical application safety issues concerning a risk of ...
Svitlana Melnik +6 more
doaj +1 more source
The polyoma virus large T binding protein p150 is a transcriptional repressor of c-MYC. [PDF]
PLoS ONE, 2012 p150, product of the SALL2 gene, is a binding partner of the polyoma virus large T antigen and a putative tumor suppressor. p150 binds to the nuclease hypersensitive element of the c-MYC promoter and represses c-MYC transcription.
Chang Kyoo Sung +8 more
doaj +1 more source
MYC is a metastasis gene for non-small-cell lung cancer. [PDF]
, 2009 Metastasis is a process by which cancer cells learn to form satellite tumors in distant organs and represents the principle cause of death of patients with solid tumors. NSCLC is the most lethal human cancer due to its high rate of metastasis.
Christian Korn +26 more
core +1 more source
Obesity under the moonlight of c-MYC
, 2023 The moonlighting protein c-Myc is a master regulator of multiple biological processes including cell proliferation, differentiation, angiogenesis, apoptosis and metabolism.
Cubero, Francisco Javier +3 more
core +1 more source
FBXO32 Targets c-Myc for Proteasomal Degradation and Inhibits c-Myc Activity [PDF]
Journal of Biological Chemistry, 2015 FBXO32 (MAFbx/Atrogin-1) is an E3 ubiquitin ligase that is markedly up-regulated in muscle atrophy. Although some data indicate that FBXO32 may play an important role in tumorigenesis, the molecular mechanism of FBXO32 in tumorigenesis has been poorly understood.
Zhichao, Mei +5 more
openaire +2 more sources
c-MYC and Epithelial Ovarian Cancer [PDF]
Frontiers in Oncology, 2021 Ovarian cancer is the deadliest of gynecological malignancies with approximately 49% of women surviving 5 years after initial diagnosis. The standard of care for ovarian cancer consists of cytoreductive surgery followed by platinum-based combination chemotherapy.
Jeyshka M. Reyes-González +2 more
openaire +3 more sources
c-Myc Suppression of DNA Double-strand Break Repair
Neoplasia: An International Journal for Oncology Research, 2012 c-Myc is a transcriptional factor that functions as a central regulator of cell growth, proliferation, and apoptosis. Overexpression of c-Myc also enhances DNA double-strand breaks (DSBs), genetic instability, and tumorigenesis. However, the mechanism(s)
Zhaozhong Li +8 more
doaj +1 more source
Transcriptional Regulation of CRD-BP by c-myc: Implications for c-myc Functions [PDF]
Genes & Cancer, 2010 The coding region determinant binding protein, CRD-BP, is a multifunctional RNA binding protein involved in different processes such as mRNA turnover, translation control, and localization. It is mostly expressed in fetal and neonatal tissues, where it regulates many transcripts essential for normal embryonic development.
Felicite K, Noubissi +3 more
openaire +2 more sources